← 返回

IL-2 联合 IL-15 通过 MAPK 信号通路增强患者自体 NK 细胞 NKG2D 受体表达以抑制肾母细胞瘤

英文原题:IL-2 Combined with IL-15 Enhanced the Expression of NKG2D Receptor on Patient Autologous NK Cells to Inhibit Wilms' Tumor via MAPK Signaling Pathway.

查看英文原题

IL-2 Combined with IL-15 Enhanced the Expression of NKG2D Receptor on Patient Autologous NK Cells to Inhibit Wilms' Tumor via MAPK Signaling Pathway.

PubMed 2022/09/30(内容时间) J Oncol

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

NK 细胞介导的细胞毒性异常可能导致 WT 的发生。对 WT 患者自体 NK 细胞进行共刺激可有效增强抗肿瘤反应,该反应涉及 NKG2D 介导的 MAPK 信号通路的激活。

研究思路结论见上方概要

免疫监视功能障碍是癌症研究的热点,可能导致多种癌症的发生和发展。然而,免疫在Wilms瘤(WT)中的潜在机制在Wilms瘤(WT)上仍不清楚。在本研究中,我们旨在研究WT中的免疫细胞并探索潜在的治疗策略。

我们基于TCGA和GEO数据库中WT患者的基因表达矩阵,使用ESTIMATE算法量化了基质评分和免疫评分。通过R studio和DAVID工具分析了差异表达基因(DEGs)和功能富集。分别使用流式细胞术、免疫荧光染色、ELISA assay和qRT-PCR检测NK细胞、细胞毒性细胞因子(INF-、PRF和GZMB)以及NK细胞受体表达。WT患者自体NK细胞经IL-2和IL-15刺激,通过LDH assay检测NK细胞对WT细胞系的细胞毒性。使用Western blot实验检测NK细胞中MAPK信号通路蛋白标志物。

ESTIMATE 显示 WT 组织的免疫评分低于邻近肾组织。同时,低免疫评分组与不良预后相关。DEG 功能富集分析显示,NK 细胞介导的细胞毒性在低免疫评分组和高免疫评分组之间存在显著差异。尽管 WT 患者中 NK 细胞比例少数有所增加,但大多数显著低于正常儿童。此外,WT 组织中 NK 细胞比例以及 INF-、PRF 和 GZMB 的表达水平低于邻近肾组织。重要的是,WT 组织中 NK 细胞的 NKG2D 表达水平显著降低。进一步,在体外,与未培养的 NK 细胞相比,IL-2 和 IL-15 能有效增强 NK 细胞杀伤 WT 细胞系的细胞毒性。FACS 和 WB 结果显示,与未培养组相比,IL-2 和 IL15 组中 NKG2D 以及 p-PI3K 与 PI3K 的比值、MEK1/2 和 p-ERK1/2 与 ERK1/2 的比值显著增加。

展开英文摘要原文

The dysfunction of immune surveillance, a hot spot in cancer research, could lead to the occurrence and development in multicancers. However, the potential mechanisms of immunity in Wilms' tumor (WT) remain unclear on Wilms' tumor (WT). In this study, we aim to investigate the immune cell in WT and explore the underlying treatment strategy. METHOD: We quantified stromal and immune scores by using ESTIMATE algorithm based on gene expression matrix of WT patients in TCGA and GEO databases. Different expression genes (DEGs) and functional enrichments were analyzed by R studio and DAVID tools. Flow cytometry, immunofluorescence staining, ELISA assay, and qRT-PCR were used for detecting the NK cells, cytotoxic cytokines (INF- , PRF, and GZMB), and NK cell receptor expression, respectively. WT patient autologous NK cells were stimulated by IL-2 and IL-15, and the cytotoxicity of NK cells against WT cell lines was detected by LDH assay. Western blot experiment was used for measuring the MAPK signaling pathway protein maker in NK cells.

ESTIMATE indicated that WT tissue had a lower immune score than adjacent kidney tissue. Meanwhile, the low immune score group was associated with poorly outcomes. DEG functional enrichment analysis showed that NK cell-mediated cytotoxicity was significantly different in low and high immune score groups. Although few of proportion of NK cells in WT patients were increased, most of that were significantly lower than normal children. Moreover, the proportion of NK cells and the expression level of INF- , PRF, and GZMB in WT tissue were lower than adjacent kidney tissue. Importantly, the NKG2D expression level of NK cells was significantly lower in WT tissue. Furthermore, in vitro, compared with uncultured NK cells, IL-2 and IL-15 could effectively enhance the cytotoxicity of NK cells on killing the WT cell lines. The FACS and WB results showed that the NKG2D and p-PI3K ratio PI3K, MEK1/2, and p-ERK1/2 ratio ERK1/2 were significantly increased in IL-2 and IL15 group compared with uncultured groups.

The abnormal NK cell-mediated cytotoxicity may cause the occurrence of WT. Costimulation of WT patients autologous NK cells could effectively enhance the antitumor reaction which involved in activation of NKG2D-mediated MAPK signaling pathway.

论文信息

作者
Li Y、Li Y、Xiang B、Tian X、Shi Q、Liu F、Lin T、Wei G
单位
Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Pediatric Research Institute, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.China
期刊
Journal of oncology2022
原文标识
PubMed 36213822 · DOI 10.1155/2022/4544773